BioGeneration Ventures

BioGeneration Ventures (BGV) is a prominent venture capital firm based in Naarden, Netherlands, specializing in early-stage European biotech companies. With over €400 million under management, BGV focuses on sectors like biopharma, medtech, and diagnostics. Their portfolio features notable investments in companies such as AcertaPharma, argenx, and New Amsterdam Pharma, underscoring their success in advancing groundbreaking scientific innovations and addressing unmet medical needs. BGV typically engages in seed to early growth stages, strategically guiding companies through clinical trials and drug development to achieve substantial exits. Their rigorous selection process ensures they back ventures with the highest potential for impactful outcomes. BGV's investment philosophy centers on combining deep scientific expertise with commercial insight to build world-class biotech firms. The firm is led by a team of experienced professionals, including managing partners Edward van Wezel and Suzanne Morsink, who bring extensive backgrounds in life sciences and venture capital. They actively support portfolio companies with strategic guidance, leveraging their broad network and industry knowledge to drive growth and innovation. BGV is committed to fostering the next generation of biotech leaders, with a clear focus on creating value for both investors and society by addressing critical health challenges through cutting-edge science and technology